Mark R. Lipstein

发表

LYMPHOID NEOPLASIA Silencing c-Myc translation as a therapeutic strategy through targeting PI3K d and CK1 « in hematological malignancies

B. Honig, N. Tatonetti, J. Vendôme, 2016 .

Silencing c-Myc Translation As a Therapeutic Strategy through Targeting PI3K Delta and CK1 Epsilon in Hematological Malignancies

B. Honig, N. Tatonetti, J. Vendôme, 2016 .

Bortezomib-induced tumor lysis syndrome in a patient with HIV-negative plasmablastic lymphoma.

G. Bhagat, O. O’Connor, L. Paoluzzi, 2010, Clinical lymphoma, myeloma & leukemia.

The Novel IKK 2 Inhibitor LY 2409881 Potently Synergizes with Histone Deacetylase Inhibitors in Preclinical Models of Lymphoma through the Downregulation of NFk B

W. Tsai, C. Deng, O. O’Connor, 2014 .

Title: the Novel Ikk2 Inhibitor Ly2409881 Potently Synergizes with Histone Deacetylase Inhibitors in Preclinical Models of Lymphoma through the Downregulation of Nf-kb Authors and Affiliations

W. Tsai, Christine, C. Deng, 2022 .

Silencing c-Myc translation as a therapeutic strategy through targeting PI3Kδ and CK1ε in hematological malignancies.

B. Honig, N. Tatonetti, J. Vendôme, 2017, Blood.

The PI3K Delta Inhibitor TGR-1202 and Proteasome Inhibitor Carfilzomib Are Highly Synergistic In Killing Human B- and T-Cell Lymphoma Cells

C. Deng, O. O’Connor, S. Viswanadha, 2013 .

PSEUDOMONAS CEPACIA IN THE RESPIRATORY FLORA OF PATIENTS WITH CYSTIC FIBROSIS (CF)

L. Laraya-Cuasay, N. Huang, Mark R. Lipstein, 1977, Pediatric Research.

The Novel IKK2 Inhibitor LY2409881 Potently Synergizes with Histone Deacetylase Inhibitors in Preclinical Models of Lymphoma through the Downregulation of NF-κB

W. Tsai, C. Deng, O. O’Connor, 2014, Clinical Cancer Research.

Combination Of Selective HDAC Inhibitors That Target Specific HDAC Isoforms Synergistically Inhibits T Cell Lymphoma

O. O’Connor, E. Holson, Charles Karan, 2013 .

Metabolic symbiosis in cancer and its therapeutic implication.

S. Bates, I. Pal, C. Deng, 2017, Seminars in oncology.